Novartis’ Acquisition of Kedalion Therapeutics

Wilson Sonsini advised Kedalion Therapeutics on the deal.

Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Wilson Sonsini Goodrich & Rosati advised Kedalion on the transaction. Kedalion is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California.

The Wilson Sonsini team included: Ken Clark (Picture), Michael Coke, Ethan Lutske, Kenji Strait, Mary Chamaki, Stephanie C. Chen, Tiffany Pan, Lowell Segal, Miruna Predescu, Tony Nguyen, Myra Sutanto Shen, Rebecca Stuart, Briza Sanchez, Andrew Velazquez, Scott McCall, Michael Klippert, Jason Chan, David Hoffmeister and Eva Yin.

Involved fees earner: Mary Chamaki – Wilson Sonsini Goodrich & Rosati; Jason Chan – Wilson Sonsini Goodrich & Rosati; Stephanie Chen – Wilson Sonsini Goodrich & Rosati; Kenneth Clark – Wilson Sonsini Goodrich & Rosati; Michael Coke – Wilson Sonsini Goodrich & Rosati; David Hoffmeister – Wilson Sonsini Goodrich & Rosati; Michael Klippert – Wilson Sonsini Goodrich & Rosati; Ethan Lutske – Wilson Sonsini Goodrich & Rosati; Scott McCall – Wilson Sonsini Goodrich & Rosati; Anthony Nguyen – Wilson Sonsini Goodrich & Rosati; Tiffany Pan – Wilson Sonsini Goodrich & Rosati; Miruna Predescu – Wilson Sonsini Goodrich & Rosati; Briza Sanchez – Wilson Sonsini Goodrich & Rosati; Lowell Segal – Wilson Sonsini Goodrich & Rosati; Kenji Strait – Wilson Sonsini Goodrich & Rosati; Rebecca Stuart – Wilson Sonsini Goodrich & Rosati; Myra Sutanto Shen – Wilson Sonsini Goodrich & Rosati; Andrew Velazquez – Wilson Sonsini Goodrich & Rosati; Eva Yin – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Kedalion Therapeutics;

Martina Bellini

Author: Martina Bellini